Joanne Donovan
Directeur Technique/Scientifique/R&D chez EDGEWISE THERAPEUTICS, INC.
Fortune : 317 158 $ au 30/04/2024
Profil
Joanne M.
Donovan is currently the Chief Medical Officer at Edgewise Therapeutics, Inc. She previously worked as the Vice President-Clinical Development at Genzyme Corp.
from 1998 to 2011, and as the Chief Medical Officer & SVP-Clinical Development at Astria Therapeutics, Inc. from 2011 to 2021.
Prior to that, she worked as the Medical Director at GelTex Pharmaceuticals, Inc. and as an Associate Clinical Professor at Harvard Medical School.
Donovan holds a doctorate degree from both Massachusetts Institute of Technology and Harvard Medical School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/05/2024 | 19 897 ( 0,02% ) | 317 158 $ | 30/04/2024 |
Postes actifs de Joanne Donovan
| Sociétés | Poste | Début |
|---|---|---|
| EDGEWISE THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 27/04/2021 |
Anciens postes connus de Joanne Donovan
| Sociétés | Poste | Fin |
|---|---|---|
| ASTRIA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 23/04/2021 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Directeur Technique/Scientifique/R&D | 01/01/2011 |
| Harvard Medical School | Corporate Officer/Principal | - |
GelTex Pharmaceuticals, Inc.
 GelTex Pharmaceuticals, Inc. BiotechnologyHealth Technology GelTex Pharmaceuticals, Inc. was developed non-absorbed, polymer-based pharmaceuticals that selectively bind and eliminate target substances from the intestinal tract. The company is a subsidiary of Geltex Corp. GelTex Pharmaceuticals was founded by Henry E Blair & James B Tananbaum in 1991 and was located in Waltham, MA. | Directeur Technique/Scientifique/R&D | - |
Formation de Joanne Donovan
| Massachusetts Institute of Technology | Doctorate Degree |
| Harvard Medical School | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ASTRIA THERAPEUTICS, INC. | Health Technology |
| EDGEWISE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
GelTex Pharmaceuticals, Inc.
GelTex Pharmaceuticals, Inc. BiotechnologyHealth Technology GelTex Pharmaceuticals, Inc. was developed non-absorbed, polymer-based pharmaceuticals that selectively bind and eliminate target substances from the intestinal tract. The company is a subsidiary of Geltex Corp. GelTex Pharmaceuticals was founded by Henry E Blair & James B Tananbaum in 1991 and was located in Waltham, MA. | Health Technology |
